Disease Atlas / Disease detail
Provides an easy explanation of the definition of congenital isolated growth hormone deficiency, its impact on growth, and the basic framework for diagnosis and management.
isolated congenital growth hormone deficiency
Start with the essentials, then explore the patient and research views.
Public revision · d6f15b59dda1
A structured guide for understanding the disease and preparing for clinical conversations.
Congenital isolated growth hormone deficiency is a condition characterized by a congenital deficiency of growth hormone without other prominent pituitary hormone deficiencies.
Representative symptoms can include a decreased rate of height growth, being shorter than peers, delayed bone age, and increased body fat.
Causes may include genetic factors related to the regulation of growth hormone secretion or abnormalities in the development of the hypothalamus-pituitary axis, and in some cases, the cause remains unidentified.
A deficiency in growth hormone can lead to decreased stimulation of the growth plates and a reduction in insulin-like growth factor-1 produced in the liver, which may slow height growth in children.
The severity of symptoms and growth patterns may vary depending on the remaining growth hormone secretion, parental height and timing of puberty, nutritional status, and comorbidities.
If left untreated, growth delay may continue, but the final adult height and overall impact vary greatly among individuals depending on the degree of deficiency and the timing of discovery, etc.
Diagnosis is determined by comprehensively evaluating growth curves and growth velocity, physical examination, family history, bone age, insulin-like growth factor-1 levels, and growth hormone stimulation test results.
Since it is difficult to diagnose with only a single growth hormone measurement, nutritional status, thyroid function, pubertal status, and the context of testing methods and results must be considered together.
Management is carried out by tracking growth and hormonal status based on the evaluation of a pediatric endocrinologist, while simultaneously addressing identified causes and associated issues.
Recombinant growth hormone replacement is a treatment that can be considered in children where growth hormone deficiency has been confirmed, but the decision to start and the method are determined by evaluating the individual's condition and risks.
In follow-up observations, height and growth rate, bone age, insulin-like growth factor-1, thyroid/adrenal function, and treatment-related adverse reactions must be interpreted over time, and participation in clinical trials alone does not confirm treatment efficacy or standard treatment.
In clinical practice, it is important to check growth curves and growth velocity, family history, pubertal status, performed tests and their interpretation, expected benefits and risks of treatment, and follow-up plans.
This material is for educational purposes and is not intended for individual diagnosis or treatment guidelines. Decisions regarding symptoms, test results, and treatment must be discussed with medical professionals.
A trial registry status does not establish efficacy or regulatory approval.
orphadata · SOURCE RECORD